Tech Company Financing Transactions
Biodel Funding Round
Biodel, based in Danbury, received investment capital from Pangaea Ventures.
Transaction Overview
Company Name
Announced On
9/13/2023
Transaction Type
Amount
Unknown
Round
Series A
Investors
Pangaea Ventures (Lead Investor) (Janelle Goulard)
Proceeds Purpose
The company intends to use the funds to accelerate commercialization of novel solutions aimed at enhancing soil health, optimizing water utilization, improving nutrient efficiency, and sequestering carbon emissions from the atmosphere.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
100 Saw Mill Rd.
Danbury, CT 06810
USA
Danbury, CT 06810
USA
Phone
Website
Email Address
Overview
Biodel Inc. is a specialty pharmaceutical company that develops novel formulations of FDA approved therapeutics to treat endocrine disorders such as diabetes. Biodel's products are created by utilizing the company's proprietary VIAdel technology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Solomon Steiner
Chief Financial Officer
Gerard Michel
Chief Medical Officer
Alan Krasner
Browse more venture capital transactions:
Prev: 9/13/2023: PanXchange venture capital transaction
Next: 9/13/2023: Enfabrica venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on every notable VC transaction. VC investment data records reported here come from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs